Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study

Nat Commun. 2015 Jul 7:6:7633. doi: 10.1038/ncomms8633.

Abstract

Graves' disease is the leading cause of hyperthyroidism affecting 1.0-1.6% of the population. Antithyroid drugs are the treatment cornerstone, but may cause life-threatening agranulocytosis. Here we conduct a two-stage association study on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide association study. We demonstrate HLA-B*38:02 (Armitage trend Pcombined=6.75 × 10(-32)) and HLA-DRB1*08:03 (Pcombined=1.83 × 10(-9)) as independent susceptibility loci. The genome-wide association study identifies the same signals. Estimated odds ratios for these two loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval=11.13-41.48) and 6.13 (95% confidence interval=3.28-11.46), respectively. Carrying both HLA-B*38:02 and HLA-DRB1*08:03 increases odds ratio to 48.41 (Pcombined=3.32 × 10(-21), 95% confidence interval=21.66-108.22). Our results could be useful for antithyroid-induced agranulocytosis and potentially for agranulocytosis caused by other chemicals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agranulocytosis / chemically induced*
  • Agranulocytosis / genetics
  • Antithyroid Agents / adverse effects*
  • Genetic Predisposition to Disease*
  • Genome-Wide Association Study*
  • Genotype*
  • HLA Antigens*
  • HLA-B Antigens
  • HLA-DRB1 Chains
  • Humans
  • Odds Ratio

Substances

  • Antithyroid Agents
  • HLA Antigens
  • HLA-B Antigens
  • HLA-DRB1 Chains